Monopar Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $18.9M | $20.3M |
| FY2022 | — | $10.1M | $8.2M |
| FY2023 | — | $5.6M | $7.3M |
| FY2024 | — | $55.0M | $45.8M |
| FY2025 | — | $137.8M | $61.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $18.9M | $20.3M |
| FY2022 | — | $10.1M | $8.2M |
| FY2023 | — | $5.6M | $7.3M |
| FY2024 | — | $55.0M | $45.8M |
| FY2025 | — | $137.8M | $61.8M |